{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T09:50:08Z","timestamp":1719136208221},"reference-count":59,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Geriatric Pharmacotherapy"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1016\/j.amjopharm.2007.09.002","type":"journal-article","created":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T05:58:50Z","timestamp":1196488730000},"page":"247-262","source":"Crossref","is-referenced-by-count":12,"title":["Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults"],"prefix":"10.1016","volume":"5","author":[{"given":"Arati V.","family":"Rao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Schmader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjopharm.2007.09.002_bib1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody ofpredefined specificity","volume":"256","author":"K\u00f6hler","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/0952-7915(89)90105-2","article-title":"Immunoglobulin structure and function: The interaction between antibody and antigen","volume":"2","author":"Sutton","year":"1989","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.2787530","article-title":"Monoclonal antibody-mediated tumor regression by induction of apoptosis","volume":"245","author":"Trauth","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib4","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1081\/CNV-100107745","article-title":"Monoclonal antibodies in the treatment of malignancy: Basic concepts and recent developments","volume":"19","author":"Dillman","year":"2001","journal-title":"Cancer Invest"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/j.seminoncol.2004.09.026","article-title":"Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer","volume":"32","author":"Collins","year":"2005","journal-title":"Semin Oncol"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib6","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10555-005-6192-2","article-title":"Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anticancer monoclonal antibodies","volume":"24","author":"Iannello","year":"2005","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00002371-199401000-00006","article-title":"Human immune response to monoclonal antibodies","volume":"15","author":"Khazaeli","year":"1994","journal-title":"J Immunother"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib8","first-page":"251","article-title":"A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words","volume":"48","author":"Mirick","year":"2004","journal-title":"QJ Nucl Med Mol Imaging"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/bjc.1992.41","article-title":"Human\/mouse chimeric antibodies show low reactivity with human anti-murine antibodies (HAMA)","volume":"65","author":"Hosono","year":"1992","journal-title":"Br J Cancer"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJM198203043060906","article-title":"Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody","volume":"306","author":"Miller","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3121\/cmr.3.3.157","article-title":"Radioimmunotherapy for non-Hodgkin's lymphoma","volume":"3","author":"Rao","year":"2005","journal-title":"Clin Med Res"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib12","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.amjopharm.2007.09.002_bib13","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [published correction appears in J Clin Oncol. 2000;18:2351]","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.amjopharm.2007.09.002_bib14","series-title":"Cancer Therapy Evaluation Program CTCAE, Version 3.0, DCTD, NCI, NIH, DHHS","year":"2003"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib15","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V82.3.807.807","article-title":"Effect of Campath-lH antibody on human hematopoietic progenitors in vitro","volume":"82","author":"Gilleece","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib16","first-page":"1476","article-title":"Effect of alemtuzumab on neoplastic B cells","volume":"89","author":"Golay","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib17","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2004-02-0593","article-title":"Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration","volume":"104","author":"Hale","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib19","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib20","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1200\/JCO.2002.06.119","article-title":"Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine","volume":"20","author":"Rai","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib21","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","article-title":"Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia","volume":"15","author":"Osterborg","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib22","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","article-title":"Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)","volume":"100","author":"Lundin","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib23","series-title":"Campath-1H: Emerging Frontline Therapy in Chronic Lymphocytic Leukemia","year":"2001"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib24","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/jcp.47.4.313","article-title":"Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas","volume":"47","author":"Salisbury","year":"1994","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib25","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/sj.leu.2403258","article-title":"Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia","volume":"18","author":"Lundin","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib26","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood-2002-10-3270","article-title":"Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia","volume":"103","author":"Rawstron","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib27","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3816\/CLM.2004.n.002","article-title":"Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia","volume":"4","author":"Keating","year":"2004","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib28","first-page":"6","article-title":"Alemtuzumab: Fatal progressive multifocal leukoencephalopathy (first report) in an elderly patient: Case report","volume":"1","year":"2006","journal-title":"Reactions"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib29","first-page":"1248","article-title":"Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: Incidence and treatment with oral ganciclovir","volume":"89","author":"Laurenti","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3816\/CLM.2002.n.016","article-title":"Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia","volume":"3","author":"Nguyen","year":"2002","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib31","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.leu.2403782","article-title":"Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia","volume":"19","author":"Lin","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3816\/CLM.2006.n.049","article-title":"Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab","volume":"7","author":"O'Brien","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2005.05789.x","article-title":"Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab","volume":"132","author":"Thursky","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib34","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1126\/science.2717946","article-title":"Calicheamicin gammall and DNA: Molecular recognition process responsible fbr site-specificity [published correction appears in Science. 1989;244:1128]","volume":"244","author":"Zein","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1021\/bc010021y","article-title":"Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia","volume":"13","author":"Hamann","year":"2002","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib36","first-page":"89","article-title":"Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model","volume":"52","author":"van der Jagt","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib37","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1177\/00912700122012751","article-title":"Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse","volume":"41","author":"Dowell","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib38","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1592\/phco.21.15.1175.33890","article-title":"Impact of age and gender on the pharmacokinetics of gemtuzumab ozogamicin","volume":"21","author":"Korth-Bradley","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.bmt.1703602","article-title":"Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: Efficacy and incidence of hepatic veno-occlusive disease","volume":"30","author":"Cohen","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib40","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib41","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.21326","article-title":"Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence","volume":"104","author":"Larson","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1389201003379059","article-title":"Rituximab: The first monoclonal antibody approved for the treatment of lymphoma","volume":"1","author":"Grillo-Lopez","year":"2000","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib44","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","article-title":"CD20: A regulator of cell-cycle progression ofB lymphocytes","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunol Today"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib45","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1016\/j.amjopharm.2007.09.002_bib46","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00001813-200211002-00002","article-title":"Mechanism of action ofrituximab","volume":"13","author":"Cerny","year":"2002","journal-title":"AntiCancer Drugs"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib47","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib48","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: Results of a Phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib49","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib50","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter Phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib51","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib52","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of retreatment","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib53","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1008389119525","article-title":"Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma","volume":"10","author":"Piro","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib54","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1200\/JCO.1999.17.6.1851","article-title":"Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a Phase II trial of rituximab","volume":"17","author":"Davis","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib55","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N EnglJ Med"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib56","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib57","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma\u2014a randomized Phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib59","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/(SICI)1096-8652(199912)62:4<247::AID-AJH9>3.0.CO;2-T","article-title":"Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: High-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia","volume":"62","author":"Yang","year":"1999","journal-title":"Am J Hematol"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib60","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1517\/14740338.4.3.599","article-title":"Reactivation of hepatitis B virus with rituximab","volume":"4","author":"Tsutsumi","year":"2005","journal-title":"Expert Opin Drug Saf"},{"issue":"Suppl 2","key":"10.1016\/j.amjopharm.2007.09.002_bib61","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/sonc.2002.30152","article-title":"Rituximab in combination with CHOP or fludarabine in low-grade lymphoma","volume":"29","author":"Czuczman","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.amjopharm.2007.09.002_bib62","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy","volume":"17","author":"Czuczman","year":"1999","journal-title":"J Clin Oncol"}],"container-title":["The American Journal of Geriatric Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1543594607000438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1543594607000438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T01:18:23Z","timestamp":1588123103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1543594607000438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S1543594607000438"],"URL":"https:\/\/doi.org\/10.1016\/j.amjopharm.2007.09.002","relation":{},"ISSN":["1543-5946"],"issn-type":[{"value":"1543-5946","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}